EVOTEC SE INH O.N.
Commented by Armin Schulz on January 21st, 2026 | 08:25 CET
Evotec, A.H.T. Syngas Technology, Deutsche Telekom: Three stocks on the verge of a decisive turning point?
Germany's economy is at a crossroads. Its old strengths are crumbling, but this is precisely what opens up opportunities for companies that are strategically realigning themselves. The key to success is not simple adaptation, but a fundamental turnaround. Three decisive paths are emerging: disruptive innovation in the biotech industry, energy production and decarbonization, and the development of sovereign digital networks. Today, we take a closer look at three companies and analyze which stocks are on the verge of a turnaround: Evotec, A.H.T. Syngas Technology, and Deutsche Telekom.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Carsten Mainitz on December 30th, 2025 | 11:15 CET
Stock Picking Alert! Power Metallic Mines – Set to Double? Puma and Evotec as Promising Turnarounds?
The 2025 stock market year has produced many winners, but also some losers. Bullish commodity markets and project progress led to a jump in the share price of Canadian commodity company Power Metallic Mines at the beginning of the year. In December, the share price corrected, but the upward trend quickly resumed, buoyed by good drilling results. The Canadian company holds one of the largest polymetallic deposits in North America, which has attracted many well-known investors this year. It is also worth taking a look at turnaround bets with takeover potential, such as Evotec and Puma.
Read
Commented by Fabian Lorenz on December 29th, 2025 | 07:00 CET
Comeback 2026! Tenfold potential? Evotec, Gerresheimer, and Desert Gold shares!
Looking for a potential ten-bagger in the gold sector? Analysts believe this could be possible for Desert Gold. The recently published PEA for the flagship gold project is triggering new price speculation. This could finally end the years-long sideways trend and allow the stock to take off. Investors had hoped for a turnaround in 2025 at Evotec. Instead, the biotech stock continued its downward trend. The strategy of the new management team does not appear to have convinced major shareholders either. Gerresheimer was an unpleasant surprise in 2025. At the turn of the year, the Company is at least engaged in damage control. But how significant is the loss of confidence?
Read
Commented by Carsten Mainitz on December 17th, 2025 | 07:35 CET
Winners for 2026: RZOLV Technologies, Evotec, Mutares have what it takes – which developments are crucial?
The 2025 stock market year was full of exciting developments. Bull markets in commodities, interest rate cuts, and geopolitical tensions. However, some companies, such as Evotec, had to deal with many home-grown problems and lagged behind the positive performance of the overall market. Mutares saw its coffers fill up, but its share price could have done better this year. Next year could be very successful for RZOLV Technologies. The Canadians are solving a major problem in gold mining.
Read
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read
Commented by Carsten Mainitz on December 11th, 2025 | 07:20 CET
On the winning side – now and in 2026: Antimony Resources and Bayer, crash at Evotec!
The year 2025 is drawing to a close. It is time to focus on stocks and investment themes that could offer attractive returns in 2026. Trends such as AI, defense, and robotics are expected to continue. Further involvement in the commodities sector also appears lucrative. Here, investors can find an exciting second-tier investment story in the still largely undiscovered Canadian company Antimony Resources. But opportunities also exist in the blue-chip segment. Bayer has established a solid foundation this year, and analysts have recently raised their price targets significantly. For heavily punished stocks like Evotec, a turnaround could also emerge next year.
Read
Commented by Fabian Lorenz on November 25th, 2025 | 07:45 CET
Buy recommendation and major order: Evotec, Nordex, Desert Gold
Are more than 100% share price gains in Nordex still not enough? Apparently not, according to analysts. In addition, the wind turbine manufacturer has secured a major order. Will the rally continue? Analysts believe that Desert Gold shares have the potential to rise by well over 100%. In their view, Desert Gold may be on the verge of one of the most significant gold discoveries in West Africa in recent years, none of which is reflected in the current share price. And what is Evotec doing? The share is trading at its lowest level since 2016. The milestone payments in the current year do not appear to be enough for investors. What do analysts say?
Read
Commented by Carsten Mainitz on November 18th, 2025 | 07:10 CET
Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!
M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read